Who
Scott Braunstein
Director
Company insider
Files Form 4 as: Director, AtaiBeckley; Director, RAPT Therapeutics; Director, Caribou Biosciences; Director, Atai Beckley; Chairman and CEO, Marinus Pharmaceuticals; Director, Trevena; Director, Constellation Pharmaceuticals; Director, Protara Therapeutics.
In numbers
- Trades disclosed
- 101
- Buys
- 3
- Sells
- 5
- Bought
- $249K
- Sold
- $226K
- Companies
- 11
- Companies where not an officer
- 9
- First trade
- 13 Jul 2015
- Last trade
- 11 Sep 2026
- Last filed
- 11 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —206,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —103,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —56,818 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —206,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —103,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —56,818 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —208,063 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —208,063 | filing |
| 4 Jun 2026filed 8 Jun 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code A | —121,968 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code A | —86,095 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code A | —121,968 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code A | —86,095 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | RAPT TherapeuticsBiotechnology | SEC FORM 4 Code U | —4,956 | filing |
| 3 Mar 2026filed 5 Mar 2026 | RAPT Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —25,000 | filing |
| 3 Mar 2026filed 5 Mar 2026 | RAPT Therapeuticsoption or derivative | SEC FORM 4 Code D | —25,000 | filing |
| 3 Mar 2026filed 5 Mar 2026 | RAPT Therapeutics | SEC FORM 4 Code U | —4,956 | filing |
| 20 Feb 2026filed 20 Feb 2026 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 20 Feb 2026filed 20 Feb 2026 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 30 Jan 2026filed 2 Feb 2026 | RAPT TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,956 at $0.00 | filing |
| 30 Jan 2026filed 2 Feb 2026 | RAPT Therapeutics | SEC FORM 4 Code A | —4,956 at $0.00 | filing |
News
Pacira BioSciences (NASDAQ:PCRX) Upgraded at JPMorgan Chase & Co.PCRX · themarketsdaily.com · 11 Oct 2026Insider Selling: Pacira BioSciences (NASDAQ:PCRX) SVP Sells $217,920.00 in StockPCRX · themarketsdaily.com · 10 Oct 2026
0 headlines in the last 90 days name Scott Braunstein; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.